Daniel Cho covers the business and financial dimensions of biotechnology and healthcare, with an emphasis on how investment trends reflect deeper shifts in innovation and risk. His reporting explores capital allocation, strategic deals, and market signals across the life sciences. At The Catalyst Brief, Daniel connects financial activity to scientific progress and policy developments to provide a more complete view of the industry.
148 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Biopharmaceutical IndustryUnder the stewardship of Belén Garijo, Sanofi is undertaking a major portfolio review, leading to the pausing of a mid-stage lung disease trial. This move signals an industry-wide trend toward sharper portfolio focus and renewed scrutiny on scientific merit.
Daniel ChoAug 6, 2026
Biopharmaceutical IndustryIndustry analysts and investors are closely watching potential merger developments between AstraZeneca and Bristol Myers Squibb, which if consummated, would create an unprecedented behemoth in the life sciences sector. This analysis explores the context, motivations, barriers, and possible impacts for companies, patients, and the broader market.
Daniel ChoAug 4, 2026
Regulatory & PolicyThe FDA advisory panel’s 10 to 3 vote in favor of Replimune’s immunotherapy, used in combination with Bristol Myers Squibb’s Opdivo for advanced melanoma, demonstrates the complexity of regulatory decision-making where clinical data present significant challenges. The trial design, deliberations, and broader industry implications are explored in depth.
Daniel ChoJul 31, 2026
Healthcare InvestmentBullseye, the new event by MedCity News targeting healthcare investors and business development leaders, has quickly established itself as an essential forum for unconventional ideas on biopharma, risk, and the future of healthcare. The conference brought forth unapologetically direct viewpoints on industry bravery, the investor landscape, and the pressure to innovate.
Daniel ChoJul 31, 2026
Regulatory & PolicyIn a pivotal move reflecting growing scrutiny of digital health companies, the U.S. Federal Trade Commission (FTC) has taken legal action against Hims & Hers. The agency alleges that the popular telehealth platform engaged in practices that not only misled consumers but also breached their privacy rights. As telemedicine adoption continues to accelerate, this lawsuit could serve as a critical inflection point for industry standards, compliance measures, and consumer trust in digital-first healthcare.
Daniel ChoJul 29, 2026
Regulatory & PolicyIn a high-stakes development for the rare disease community and the biopharmaceutical industry, the FDA has publicly disagreed with Capricor’s assertion that its Phase 3 trial for a Duchenne muscular dystrophy (DMD) cell therapy met its primary outcome. As advisory committee deliberations approach, the debate underscores persistent challenges in clinical trial interpretation and the regulatory approval process.
Daniel ChoJul 27, 2026
Biopharmaceutical IndustryIn a move set to reshape the peptide drug manufacturing landscape, Samsung Biologics has announced plans to acquire PolyPeptide for $1.8 billion. The acquisition is seen as a strategic response to surging demand for GLP-1 and similar obesity medications.
Daniel ChoJul 21, 2026
Medical TechnologyAs clinical algorithms proliferate in modern healthcare, concerns about validity and bias have also increased. MDCalc’s new system sets out to bring more transparency and rigor to the digital tools underpinning millions of daily medical decisions.
Daniel ChoJul 19, 2026
Regulatory & PolicyThe increasing occurrence of hazardous wildfire smoke events in the U.S. and Canada has forced policy makers, scientists, and health officials to revisit the regulatory playbook. By reflecting on the history of smog regulation in the twentieth century, this post examines the potential pathways and pitfalls for addressing present-day challenges in air quality management.
Daniel ChoJul 19, 2026
Regulatory & PolicyA recent letter from the FDA’s acting director to Congressional leadership clarifies that certain peer-reviewed papers do not reflect agency policy or its interpretation of regulatory issues. The move comes amid lawmaker criticism about potential overreach and confusion in health policy debates.
Daniel ChoJul 19, 2026
Regulatory & PolicyThe push for annual testosterone screenings in the military is presented as a public health and readiness initiative, but experts warn that such a move could introduce a host of unexpected clinical and social complications. This article explores the multifaceted debate, examining the science, policy aims, and unintended consequences that could emerge from widespread hormone screening.
Daniel ChoJul 19, 2026
Regulatory & PolicyWith the 2027 Physician Fee Schedule, the Centers for Medicare and Medicaid Services (CMS) proposes major restrictions on remote patient monitoring (RPM) in response to reports of widespread abuse. This analysis dives into the motivations, possible ripple effects, and the broader context surrounding CMS’s controversial move, as well as its impact on digital health innovation, patient engagement, and chronic disease care.
Daniel ChoJul 17, 2026